Quick Answer
Monopar Therapeutics reported Stockholders Equity of $137.83 million for fiscal year 2025.
Monopar Therapeutics Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $137.83M | +150.4% |
| 2024 | $55.04M | +885.0% |
| 2023 | $5.59M | -44.6% |
| 2022 | $10.09M | -46.7% |
| 2021 | $18.94M | +20.7% |
| 2020 | $15.69M | +24.3% |
| 2019 | $12.63M | +82.5% |
| 2018 | $6.92M | -28.1% |
| 2017 | $9.62M | +239.8% |
| 2016 | $2.83M | +2.8% |
| 2015 | $2.75M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $141.56M | +2761.6% | +171.2% |
| June 30, 2025 | $52.20M | +757.1% | -2.6% |
| March 31, 2025 | $53.59M | +616.8% | -2.6% |
| December 31, 2024 | $55.04M | +885.0% | +1012.6% |
| September 30, 2024 | $4.95M | -25.2% | -18.8% |
| June 30, 2024 | $6.09M | -22.3% | -18.5% |
| March 31, 2024 | $7.48M | -16.4% | +33.8% |
| December 31, 2023 | $5.59M | -44.6% | -15.5% |
- Monopar Therapeutics showed an increase of +150.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2015–2025 period, Monopar Therapeutics’s stockholders equity has grown by 4904.4% (from $2.75 million to $137.83 million).
- The most recent figure is from Monopar Therapeutics’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: